Tysabri and PML: Symptoms, Monitoring, and Next Steps

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Drug Safety Concerns

If you or a loved one are experiencing new neurological symptoms while on Tysabri, it's natural to wonder how they connect to PML. This page provides clear, factual information on symptom recognition and the importance of timely follow-up. Building on decades of pharmacovigilance research, we outline what you need to know about monitoring and next steps.

Medical Background and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Pennsylvania who have developed PML after Tysabri exposure, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri increases the risk of PML, and the prescribing information includes a boxed warning emphasizing this danger (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing Tysabri therapy, weighing expected benefit against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation, Diagnosis, and Mechanistic Pathways

PML presents with progressive neurological deficits, including cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. Healthcare professionals are instructed to monitor patients on Tysabri for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because PML can progress rapidly, early recognition is essential. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for multiple sclerosis but also impairs immune surveillance against JC virus. Under normal conditions, JC virus is controlled by the immune system; however, Tysabri-mediated blockade of lymphocyte trafficking allows the virus to reactivate and infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. This mechanism explains why patients with anti-JCV antibodies—indicating prior JC virus exposure—are at higher risk.

Adequacy of Warnings and Settlement Considerations

The FDA-approved labeling for Tysabri includes a boxed warning that clearly states the increased risk of PML and identifies the three major risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether warnings were adequately communicated to individual patients, particularly regarding the cumulative risk over time and the significance of anti-JCV antibody status. For patients in Pennsylvania who have developed PML after Tysabri use, potential legal claims may involve product liability, failure to warn, or negligence. A key factor is the statute of limitations, which in Pennsylvania for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. Given that PML symptoms can develop insidiously and diagnosis may be delayed, the timeline between Tysabri exposure and documented harm is critical. The boxed warning notes that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and the duration of treatment prior to onset can range from a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should consult with a qualified attorney promptly to assess their individual circumstances and ensure compliance with filing deadlines.

Timeline Between Exposure and Documented Harm

The risk of PML increases with longer Tysabri treatment, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported after shorter durations. The onset of PML symptoms may be gradual, and diagnosis often requires MRI and CSF analysis. Once diagnosed, the prognosis is poor, with most patients experiencing severe disability or death. For legal purposes, the 'date of injury' is typically the date of diagnosis or when symptoms first became apparent, whichever is earlier. Pennsylvania courts generally apply the discovery rule, meaning the statute of limitations begins when the plaintiff knew or should have known of the injury and its cause. Tysabri-associated PML is a devastating condition with well-characterized risk factors and a clear mechanistic basis. While the drug's labeling includes prominent warnings and a restricted distribution program, affected patients in Pennsylvania must be aware of the two-year statute of limitations from the date of discovery. Given the severity of PML and the potential for delayed diagnosis, prompt legal consultation is advisable. The medical evidence underscores the importance of monitoring for PML symptoms and considering risk factors when prescribing Tysabri.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. This is known as the discovery rule. Because PML symptoms can develop gradually and diagnosis may be delayed, it is crucial to consult with an attorney promptly to determine the applicable deadline for your case.

What are the main risk factors for developing PML while on Tysabri?

The three major risk factors for Tysabri-associated PML are: the presence of anti-JCV antibodies (indicating prior JC virus exposure), longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications. These factors are identified in the FDA-approved labeling and should be considered when assessing the risk-benefit of Tysabri therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.